诺泰生物(688076) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥140,873,674.91, a decrease of 11.09% compared to the same period last year[8] - Net profit attributable to shareholders for Q3 2021 was ¥37,164,514.31, an increase of 4.67% year-over-year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 30.80% to ¥18,359,658.26[8] - Total revenue for the first three quarters of 2021 reached ¥449,877,162.41, an increase of 20.1% compared to ¥374,726,793.63 in the same period of 2020[32] - Net profit for the first three quarters of 2021 was ¥84,825,337.97, compared to ¥78,888,059.93 in 2020, representing a year-on-year increase of 7.4%[39] - The total comprehensive income attributable to the parent company reached CNY 88,582,488.17, an increase from CNY 83,893,484.58 in the same period last year, reflecting a growth of approximately 8.1%[41] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,024,142,599.47, an increase of 45.04% compared to the end of the previous year[12] - The total assets increased to ¥2,024,142,599.47, up from ¥1,395,573,459.13, marking a growth of 45%[32] - The total liabilities of the company as of September 30, 2021, were not explicitly stated but are crucial for assessing financial health[27] - Non-current liabilities decreased to ¥26,809,096.01 from ¥47,338,215.16, a reduction of 43.4%[32] - The company reported a significant reduction in short-term borrowings, decreasing from ¥177,947,037.55 to ¥56,839,615.05, a drop of 68.1%[32] Shareholder Information - The number of shareholders at the end of the reporting period was 12,846, with the top ten shareholders holding a combined 39.88% of the shares[21] - The largest shareholder, Lianyungang Nuotai Investment Management Partnership, held 9.38% of the shares, totaling 20 million shares[21] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥131,827,280.03, an increase of 32.04% compared to the same period last year[12] - The net cash flow from operating activities was CNY 131,827,280.03, up from CNY 99,840,845.29, representing a year-over-year increase of about 32.1%[43] - Cash inflow from investment activities totaled CNY 638,790,339.17, significantly higher than CNY 49,997,237.92 in the previous year, indicating a substantial increase in investment recovery[43] - The net cash flow from financing activities was CNY 521,003,577.78, compared to CNY 40,676,922.91 in the same period last year, showing a remarkable increase[43] - The cash inflow from sales of goods and services was CNY 476,520,549.55, compared to CNY 376,279,416.67 in the previous year, marking an increase of about 26.6%[43] - The net increase in cash and cash equivalents for the period was CNY 450,175,389.71, a significant rise from CNY 14,840,289.98 in the same period last year[46] Research and Development - R&D expenses for Q3 2021 totaled ¥13,769,947.43, a decrease of 38.41% compared to the same period last year, representing 9.77% of operating revenue[12] - Research and development expenses for the first three quarters were ¥44,422,127.37, slightly up from ¥43,349,679.30, indicating a focus on innovation[35] Other Financial Metrics - Basic earnings per share for Q3 2021 were ¥0.18, a decrease of 18.18% year-over-year[12] - The weighted average return on equity for Q3 2021 was 2.11%, a decrease of 1.82 percentage points compared to the same period last year[12] - The company reported a basic and diluted earnings per share of CNY 0.48, down from CNY 0.52 in the previous year, reflecting a decrease of approximately 7.7%[41] Government Support and Market Strategy - The company received government subsidies amounting to ¥20,914,912.93 during the reporting period[12] - The company plans to expand its market presence and invest in new product development to drive future growth[32] Inventory and Receivables - Inventory levels rose to ¥236.94 million, up from ¥184.99 million, representing an increase of about 28% year-over-year[27] - The company's accounts receivable stood at ¥104.41 million, slightly decreasing from ¥107.42 million, showing a decline of around 2%[27] Currency Impact - The company experienced a foreign exchange loss of CNY 571,773.16, compared to a loss of CNY 3,975,556.23 in the previous year, indicating an improvement in currency impact[46] No Significant Changes - The company has not disclosed any new product developments or technological advancements during this reporting period[24] - There are no significant mergers or acquisitions reported in the current financial period[24]